Vicarious Surgical Earnings Call Transcripts
Fiscal Year 2025
-
Management announced a $5 million reduction in 2025 cash burn guidance and plans to provide 2026 guidance before year-end. The company is focused on developing a production-equivalent robotic system, targeting design freeze by end of 2025 and first-in-human trials in 2027. Increased transparency and operational discipline are central to the new strategy.
-
Q3 2025 saw a 35% year-over-year reduction in operating expenses and improved net loss per share, driven by cost-cutting and outsourcing initiatives. The design freeze milestone remains targeted for year-end 2026, with ongoing efforts to reduce cash burn and maintain strong hospital partnerships.
-
A new robotic surgical system aims to address the limitations of current platforms by offering enhanced dexterity, visualization, and intra-abdominal access, initially targeting ventral hernia repair. With 82% of U.S. procedures still non-robotic, the company seeks to capture untapped market share through differentiated technology and a focused commercialization plan.
-
Leadership transition and a strategic shift to prioritize completion of a production-equivalent system have delayed clinical trial timelines. Q2 2025 saw reduced expenses and net loss, with cash burn in line with guidance. Updated milestones will follow a four to six week assessment.
-
Q1 2025 saw reduced operating expenses and improved net loss per share, with $37 million in cash and a $12 million quarterly cash burn. Progress continued toward first clinical cases, supported by new hospital partnerships and effective supply chain management.
Fiscal Year 2024
-
Key 2024 milestones included successful Version 1.0 System integration, expanded hospital partnerships, and improved financial discipline with reduced losses and cash burn. First clinical cases are expected late 2025, with regulatory submissions targeted mid-year.
-
Q3 2024 saw a 17% year-over-year drop in operating expenses and improved adjusted net loss, as integration of the single-port system nears completion. First-in-human studies are set for 2025, with a strong cash position supporting clinical milestones.
-
Progress continues on the V1.0 system, with integration on track for fall and first clinical patient expected in 2025. Q2 operating expenses rose 17% year-over-year, but cash burn remains in line with guidance, leaving $73 million in cash and a 1.5-year runway.
-
The meeting covered director elections, amendments to the equity plan and certificate of incorporation, and auditor ratification, with all proposals approved. No questions were raised by stockholders, and management highlighted standard forward-looking risks.